More than a common acid buffering in the treatment of Non-Erosive GERD-like Clinical Spectrum: A Chios Masthia-based Formulation with (Cyto) Protecting Effect
<p>The aim of this study was to test the clinical and mucosal benefit of a natural gastro-oesophageal mucosal protector DOGDG-121 in non-erosive GERD comprising from NERD, to Functional Heartburn and Hypersensitive oesophagus while also ascertain the symptom-free duration in patients with prio...
Bewaard in:
Hoofdauteurs: | , , , , , , |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Archives of Clinical Gastroenterology - Peertechz Publications,
2019-02-26.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | peertech__10_17352_2455-2283_000060 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Barreto R |e author |
700 | 1 | 0 | |a Todai M |e author |
700 | 1 | 0 | |a Kumar N |e author |
700 | 1 | 0 | |a Hayakawa K |e author |
700 | 1 | 0 | |a Marotta F |e author |
700 | 1 | 0 | |a Imaoka Y |e author |
700 | 1 | 0 | |a Catanzaro R |e author |
245 | 0 | 0 | |a More than a common acid buffering in the treatment of Non-Erosive GERD-like Clinical Spectrum: A Chios Masthia-based Formulation with (Cyto) Protecting Effect |
260 | |b Archives of Clinical Gastroenterology - Peertechz Publications, |c 2019-02-26. | ||
520 | |a <p>The aim of this study was to test the clinical and mucosal benefit of a natural gastro-oesophageal mucosal protector DOGDG-121 in non-erosive GERD comprising from NERD, to Functional Heartburn and Hypersensitive oesophagus while also ascertain the symptom-free duration in patients with prior symptomatic relapsing GERD. 68 consecutive adult patients, reporting mild heartburn symptoms two or more days a week or at least moderate symptoms more than once a week for at least six months duration were prospectively recruited. Inclusion criteria were: recurrent typical GERD symptoms, such as heartburn and/or acid regurgitation and a duration of symptoms>6 months. Patients were divided in two groups comparable as for age, gender, BMI and pHmetry profile. One group was given 1 sachet a day (2gr) of DOGDG-121 (chios masthia- and musa extract-based phytocompound, Reflumed, Named, Italy) quickly stirred in a small water quantity (≤30ml) and swallowed at once, while the other was administered 5ml of a buffering antacid suspension (BAS) (Dried Aluminium Hydroxide Gel 230mg,Magnesium Hydroxide 200mg Simeticone 25mg)as positive control. At entry and after 12 weeks all patients underwent an ambulatory 24-Hours intraesophageal pH monitoring. As compared to BAS, DOGDG-121 enabled a significantly lesser degree of microscopic oesophagitis, reduced gene expression of IL-8 and all Eotaxins tested (p<0.05). This was also associated to a better gastrointestinal-related quality of life assessment (p<0.05). This strongly suggested that, besides protection against acido-peptic mucosal injury per sè, DOGDG-121 appears to offer a more significant effect on inflammatory mediators interfering with peripheral nociceptors, being amenable to safe, long-term cytoprotective use.</p> | ||
540 | |a Copyright © Barreto R et al. | ||
546 | |a en | ||
655 | 7 | |a Research Article |2 local | |
856 | 4 | 1 | |u https://doi.org/10.17352/2455-2283.000060 |z Connect to this object online. |